Mackall, C.L. & Gress, R.E. Thymic aging and T-cell regeneration. Immunol. Rev. 160, 91–102 (1997).
Grunebaum, E., Sharfe, N. & Roifman, C.M. Human T cell immunodeficiency: when signal transduction goes wrong. Immunol. Res. 35, 117–126 (2006).
Fischer, A. et al. Naturally occurring primary deficiencies of the immune system. Annu. Rev. Immunol. 15, 93–124 (1997).
Chinen, J., Finkelman, F. & Shearer, W.T. Advances in basic and clinical immunology. J. Allergy Clin. Immunol. 118, 489–495 (2006).
Lehrnbecher, T., Foster, C., Vázquez, N., Mackall, C.L. & Chanock, S.J. Therapy-induced alterations in host defense in children receiving therapy for cancer. J. Pediatr. Hematol. Oncol. 19, 399–417 (1997).
Yarilin, A.A. et al. Late T cell deficiency in victims of the Chernobyl radiation accident: possible mechanisms of induction. Int. J. Radiat. Biol. 63, 519–528 (1993).
Appelbaum, F.R. Haematopoietic cell transplantation as immunotherapy. Nature 411, 385–389 (2001).
Joao, C. et al. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant. 37, 865–871 (2006).
Leemhuis, T., Wells, S., Scheffold, C., Edinger, M. & Negrin, R.S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. 11, 181–187 (2005).
Gordan, L.N. et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma. Bone Marrow Transplant. 31, 1009–1013 (2003).
Porrata, L.F. et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 16, 1311–1318 (2002).
Porrata, L.F. et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br. J. Haematol. 117, 629–633 (2002).
Porrata, L.F. et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98, 579–585 (2001).
Porrata, L.F., Ingle, J.N., Litzow, M.R., Geyer, S. & Markovic, S.N. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant. 28, 865–871 (2001).
Kolb, H.J. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86, 2041–2050 (1995).
Gottschalk, S., Heslop, H.E. & Rooney, C.M. Adoptive immunotherapy for EBV-associated malignancies. Leuk. Lymphoma 46, 1–10 (2005).
Gottschalk, S., Heslop, H.E. & Rooney, C.M. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv. Cancer Res. 84, 175–201 (2002).
Rooney, C.M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549–1555 (1998).
Rooney, C.M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet 345, 9–13 (1995).
Heslop, H.E., Brenner, M.K. & Rooney, C.M. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331, 679–680 (1994).
Yotnda, P. et al. Cytotoxic T cell response against the chimeric p210 BCR–ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101, 2290–2296 (1998).
Luznik, L. et al. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 101, 1645–1652 (2003).
Schmitt, T.M. & Zúñiga-Pflücker, J.C. Induction of T cell development from hematopoietic progenitor cells by Delta-like-1 in vitro. Immunity 17, 749–756 (2002).
Ohishi, K., Varnum-Finney, B. & Bernstein, I.D. Delta-1 enhances marrow and thymus repopulating ability of human CD34(+)CD38(−)cord blood cells. J. Clin. Invest. 110, 1165–1174 (2002).
De Smedt, M., Hoebeke, I. & Plum, J. Human bone marrow CD34+ progenitor cells mature to T cells on OP9–DL1 stromal cell line without thymus microenvironment. Blood Cells Mol. Dis. 33, 227–232 (2004).
La Motte-Mohs, R.N., Herer, E. & Zúñiga-Pflücker, J.C. Induction of T cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood 105, 1431–1439 (2005).
Zakrzewski, J.L. et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat. Med. 12, 1039–1047 (2006).
Dallas, M.H., Varnum-Finney, B., Martin, P.J. & Bernstein, I.D. Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1. Blood 109, 3579–3587 (2007).
Schmitt, T.M. et al. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat. Immunol. 5, 410–417 (2004).
Cooke, K.R. et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88, 3230–3239 (1996).
Hill, G.R. et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90, 3204–3213 (1997).
Acha-Orbea, H. & MacDonald, H.R. Superantigens of mouse mammary tumor virus. Annu. Rev. Immunol. 13, 459–486 (1995).
Abe, R., Kanagawa, O., Sheard, M.A., Malissen, B. & Foo-Phillips, M. Characterization of a new minor lymphocyte stimulatory system. I. Cluster of self antigens recognized by “I-E-reactive” V beta s, V beta 5, V beta 11, and V beta 12 T cell receptors for antigen. J. Immunol. 147, 739–749 (1991).
Woodland, D., Happ, M.P., Bill, J. & Palmer, E. Requirement for cotolerogenic gene products in the clonal deletion of I-E reactive T cells. Science 247, 964–967 (1990).
Bill, J., Kanagawa, O., Woodland, D.L. & Palmer, E. The MHC molecule I-E is necessary but not sufficient for the clonal deletion of V beta 11-bearing T cells. J. Exp. Med. 169, 1405–1419 (1989).
Vacchio, M.S. & Hodes, R.J. Decreased expression of specific V beta families is associated with expression of multiple MHC and non-MHC gene products. J. Exp. Med. 170, 1335–1346 (1989).
Anderson, G. & Jenkinson, E.J. Lymphostromal interactions in thymic development and function. Nat. Rev. Immunol. 1, 31–40 (2001).
Kessels, H.W., Wolkers, M.C., van den Boom, M.D., van der Valk, M.A. & Schumacher, T.N. Immunotherapy through TCR gene transfer. Nat. Immunol. 2, 957–961 (2001).
Brentjens, R.J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279–286 (2003).
Sadelain, M., Riviere, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35–45 (2003).
Morgan, R.A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
Zhao, Y. et al. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res. 67, 2425–2429 (2007).
Bousso, P., Bhakta, N.R., Lewis, R.S. & Robey, E. Dynamics of thymocyte-stromal cell interactions visualized by two-photon microscopy. Science 296, 1876–1880 (2002).
Ernst, B.B., Surh, C.D. & Sprent, J. Bone marrow-derived cells fail to induce positive selection in thymus reaggregation cultures. J. Exp. Med. 183, 1235–1240 (1996).
Bix, M. & Raulet, D. Inefficient positive selection of T cells directed by haematopoietic cells. Nature 359, 330–333 (1992).
Wu, L., Li, C.L. & Shortman, K. Thymic dendritic cell precursors: relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J. Exp. Med. 184, 903–911 (1996).
Shen, H.Q. et al. T/NK bipotent progenitors in the thymus retain the potential to generate dendritic cells. J. Immunol. 171, 3401–3406 (2003).
Liggins, A.P., Guinn, B.A. & Banham, A.H. Identification of lymphoma-associated antigens using SEREX. Methods Mol. Med. 115, 109–128 (2005).
Greiner, J. et al. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 108, 4109–4117 (2006).
Cohen, J.I. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. Semin. Hematol. 40, 116–123 (2003).
Yang, L., Qin, X.F., Baltimore, D. & van Parijs, L. Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proc. Natl. Acad. Sci. USA 99, 6204–6209 (2002).
June, C.H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117, 1466–1476 (2007).
Terwey, T.H. et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood 106, 3322–3330 (2005).
May, C. et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 406, 82–86 (2000).
Vardi, Y., Ying, Z. & Zhang, C.H. Two-sample tests for growth curves under dependent right censoring. Biometrika 88, 949–960 (2001).